{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gastroenteritis/background-information/complications/","result":{"pageContext":{"chapter":{"id":"2e6d28a0-305f-5c3c-983a-62e1631c41b8","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 0b555e53-208d-4988-af39-51f19e3323a0 --><h2>What are the complications?</h2><!-- end field 0b555e53-208d-4988-af39-51f19e3323a0 -->","summary":"","htmlStringContent":"<!-- begin item 7815efc0-ae87-42b0-aab6-1745a2a2c50d --><!-- begin field 20703b95-5edb-4778-9a84-2a976e663043 --><p><strong>The risk of complications from gastroenteritis is greatest in infants and young children, pregnant women, the elderly, and people with co-morbid conditions including the immunocompromised </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Guarino, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Shane, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>]<strong>. Possible complications include:</strong></p><ul><li>Dehydration, electrolyte disturbance, and acute kidney injury (AKI)<ul><li>Dehydration from excess fluid loss, electrolyte disturbance, and AKI may follow severe infection, if fluid input does not equal or exceed fluid output [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Guarino, 2014</a>]. Rarely, severe dehydration can cause hypovolaemic shock, coma, and death [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Banyai, 2018</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/acute-kidney-injury/\">Acute kidney injury</a> for more information.</li></ul></li><li>Haemorrhagic colitis<ul><li>This can be a complication from Shiga toxin-producing <em>Escherichia coli </em>(STEC) that typically presents with acute bloody diarrhoea and severe abdominal pain in children lasting for 2 weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2017</a>].</li></ul></li><li>Haemolytic uraemic syndrome (HUS)<ul><li>This is a rare but potentially life-threatening complication of acute infectious gastroenteritis that occurs mostly in children aged less than 5 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li><li>About 10% of STEC 0157 cases develop HUS after an initial prodrome of gastroenteritis or haemorrhagic colitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2017</a>]. It may also be associated with <em>Shigella dysenteriae</em> and <em>Campylobacter </em>spp. infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li><li>It is characterized by AKI, thrombocytopenia, and microangiopathic haemolytic anaemia, usually 1 week after the onset of bloody diarrhoea. About 50% of those affected develop chronic renal complications. Mortality rates are between 3–5% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li></ul></li><li>Thrombotic thrombocytopaenic purpura (TTP)<ul><li>This primarily affects adults infected with STEC, and can present with fever, flu-like symptoms, petechial haemorrhages on the lower limbs, haematuria, anaemia, renal dysfunction, and possible neurological deficits [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2017</a>].</li></ul></li><li>Reactive arthritis including Reiter's syndrome<ul><li>This may be associated with <em>Campylobacter </em>spp., <em>Shigella flexneri</em>, and <em>Yersinia enterocolitica</em> infection. Reiter's syndrome describes a combination of urethritis, inflammatory arthritis, and uveitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li></ul></li><li>Aortitis, osteomyelitis<ul><li>These may be associated with <em>Salmonella</em> spp. and <em>Yersinia</em> spp. infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Shane, 2017</a>].</li></ul></li><li>Sepsis<ul><li>Invasive infection with <em>Salmonella</em> spp. and <em>Yersinia enterocolitica</em> may lead to sepsis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sepsis/\">Sepsis</a> for more information.</li></ul></li><li>Toxic megacolon<ul><li>This can rarely occur in people with rotavirus gastroenteritis or severe travellers' diarrhoea, for example [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Barrett, 2016</a>].</li></ul></li><li>Pancreatitis, sclerosing cholangitis, and liver cirrhosis<ul><li>This may complicate <em>Cryptosporidium</em> spp. infection, particularly in the immunocompromised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>]. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pancreatitis-acute/\">Pancreatitis - acute</a> and <a class=\"topic-reference external-reference\" href=\"/topics/jaundice-in-adults/\">Jaundice in adults</a> for more information.</li></ul></li><li>Faltering growth<ul><li>Infection with <em>Giardia</em> spp. can cause weight loss due to malabsorption, and chronic infection in children can lead to faltering growth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Minetti, 2016</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/faltering-growth/\">Faltering growth</a> for more information.</li></ul></li><li>Chronic diarrhoea<ul><li>Chronic intractable diarrhoea for weeks, months, or longer may occur with <em>Giardia</em> spp. and <em>Cryptosporidium</em> spp. infection and viral gastroenteritis, particularly in people who are immunocompromised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Banyai, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li></ul></li><li>Irritable bowel syndrome (IBS)<ul><li>Gastrointestinal infection including travellers' diarrhoea is a risk factor for the development of post-infectious IBS. It affects between 3% and over 30% of people after infectious gastroenteritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Schwille-Kiuntke, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Riddle, 2017</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/irritable-bowel-syndrome/\">Irritable bowel syndrome</a> for more information.</li></ul></li><li>Inflammatory bowel disease (IBD)<ul><li>There is an increased risk of incident IBD following non-typhoidal salmonella, <em>Campylobacter</em> spp., and <em>Clostridium difficile</em> infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Keithlin, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Axelrad, 2020</a>]. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/crohns-disease/\">Crohn's disease</a> and <a class=\"topic-reference external-reference\" href=\"/topics/ulcerative-colitis/\">Ulcerative colitis</a> for more information.</li></ul></li><li>Acquired or secondary lactose intolerance<ul><li>Lactase deficiency occurs in up to 40% of people with giardiasis, and can persist for several weeks after parasite eradication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Minetti, 2016</a>].</li></ul></li><li>Guillain-Barré syndrome<ul><li>Guillain-Barré syndrome is associated with different viruses, and may be rarely associated with <em>Campylobacter</em> spp. infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Shane, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li></ul></li><li>Meningitis<ul><li>Infants under 3 months of age with <em>Salmonella</em> spp. infection are at particularly high risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Shane, 2017</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/\">Meningitis - bacterial meningitis and meningococcal disease</a> for more information.</li></ul></li><li>Invasive entamoeba infection<ul><li>Rarely, extraintestinal disease occurs when <em>Entamoeba histolytica</em> invades the liver causing abscesses, which can be life threatening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">PHE, 2020a</a>].</li></ul></li></ul><!-- end field 20703b95-5edb-4778-9a84-2a976e663043 --><!-- end item 7815efc0-ae87-42b0-aab6-1745a2a2c50d -->","topic":{"id":"b4861e4a-0cf5-5fed-b83a-a57e60b78a80","topicId":"f3241704-6943-4c6f-9689-cf06812d0832","topicName":"Gastroenteritis","slug":"gastroenteritis","lastRevised":"Last revised in August 2020","chapters":[{"id":"6d884ff2-d64b-55ab-aae4-78f940a95f30","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b8c6f38-638e-5804-8318-e1b14304e522","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"94101b20-12cb-5041-a413-6dcc12af895e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f4287eb4-029e-5263-ae00-6b8ece9aff32","slug":"changes","fullItemName":"Changes"},{"id":"4d578aaa-9662-5914-903d-e36514be32a0","slug":"update","fullItemName":"Update"}]},{"id":"d01dac38-120c-51d7-a620-b85d40b1eb15","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd1552a6-5a2d-563b-a242-29bd94992517","slug":"goals","fullItemName":"Goals"},{"id":"b7b0c03c-8588-5565-82d9-9cfe2d111d41","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b32a632a-610d-59de-bf5f-d79f466a66b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"28e54d5a-177d-5e18-9753-67134efb41a6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2b2f62eb-7996-5b9c-88ed-3648b2e3721d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"1e2a0d5e-dba9-54fe-99e1-1e33dd814faa","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d382f491-ad27-5dbc-bfa7-806501a73eb5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6b1334e-cda3-5363-a887-f24bcde0b626","slug":"definition","fullItemName":"Definition"},{"id":"501c659b-1656-5ad1-b381-f3042ed81bec","slug":"causes","fullItemName":"Causes"},{"id":"2e6d28a0-305f-5c3c-983a-62e1631c41b8","slug":"complications","fullItemName":"Complications"}]},{"id":"71e06d5f-9179-5a88-986f-34fd82eab600","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"de24a8b0-cda2-5be8-8fbf-df6ddf6fb6eb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3f17076e-616a-532c-a5ee-d6a5d2104dc5","slug":"assessment","fullItemName":"Assessment"},{"id":"bf8cbeb8-b0a5-5ebc-9cfc-7ba3beb62c6b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"34db7d00-7fa0-5e11-a2b2-0e045c80e236","fullItemName":"Management","slug":"management","subChapters":[{"id":"64ea9cd1-ae9b-5d77-bc7b-1df0c42b3d66","slug":"child-gastroenteritis","fullItemName":"Scenario: Child gastroenteritis"},{"id":"97ae699a-60c4-5649-a4ad-f0bbdf5c7aa5","slug":"adult-gastroenteritis","fullItemName":"Scenario: Adult gastroenteritis"}]},{"id":"3874a053-755a-5518-961d-b6811d36d278","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6969159-fdcf-5f1f-ac9a-c8bcf291abdc","slug":"tinidazole","fullItemName":"Tinidazole"},{"id":"ddc9423c-8dd0-5c5b-b208-f261c2cd777d","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"84f507dc-726d-559a-b788-9c91297b0fd0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2e6aa3b5-4c48-538f-bc1e-8c97a0e4940e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"60c6fc26-4bfa-5e0d-bba6-0ebffc61d83b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0cb4826a-19bb-549f-b65f-2f5ad75883bc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b05f7822-56ab-538c-9fb0-fd20a99810a2","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8bc3886a-0fd7-52a0-9be2-506de8584bc9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a0898f71-226b-5af6-87b5-20b9c6c1fe78","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52fa5fd-99e9-5dd5-b626-0e429b2424e3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d382f491-ad27-5dbc-bfa7-806501a73eb5","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}